Literature DB >> 8605607

Molybdenum and copper kinetics after tetrathiomolybdate injection in LEC rats: specific role of serum albumin.

K T Suzuki1, Y Ogra, M Ohmichi.   

Abstract

Chelation therapy with tetrathiomolybdate (TTM) was applied to Long-Evans rats with a cinnamon coat-color (LEC rats), an animal model for Wilson disease, to remove copper (Cu) accumulated in the liver in a form bound to metallothionein (MT). Changes in molybdenum (Mo) and Cu concentrations and their biological forms in serum of LEC rats determined at different times after a single intraperitoneal injection were compared with those of Wistar (normal) rats. The change in Mo concentration in serum of normal rats was mono-phasic, whereas in LEC rats it was bi-phasic. The phase in normal rats and the first phase in LEC rats appeared to reflect the process of uptake and disappearance of TTM in the livers of Wistar and LEC rats. On the other hand, the second phase in LEC rats paralleled the changes of Cu and appeared to reflect the complex formation (Cu/thiomolybdate complex) between Mo and Cu accumulated in the liver. The complex was specifically bound to albumin as determined by high performance liquid chromatography with inductively coupled plasma-mass spectrometry (HPLC/ICP-MS). The results suggested that the changes in the Mo concentration in serum reflected the amount of Cu in the liver.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8605607     DOI: 10.1016/S0946-672X(11)80043-X

Source DB:  PubMed          Journal:  J Trace Elem Med Biol        ISSN: 0946-672X            Impact factor:   3.849


  2 in total

1.  Nutrigenomics analysis reveals that copper deficiency and dietary sucrose up-regulate inflammation, fibrosis and lipogenic pathways in a mature rat model of nonalcoholic fatty liver disease.

Authors:  Savannah Tallino; Megan Duffy; Martina Ralle; María Paz Cortés; Mauricio Latorre; Jason L Burkhead
Journal:  J Nutr Biochem       Date:  2015-05-15       Impact factor: 6.048

2.  Copper Chelation Inhibits BRAFV600E-Driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors.

Authors:  Donita C Brady; Matthew S Crowe; Danielle N Greenberg; Christopher M Counter
Journal:  Cancer Res       Date:  2017-10-06       Impact factor: 12.701

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.